2020 was a year we will never forget for reasons beyond trading. The last 15 months might have marked a turning point in the healthcare sector specifically regarding the drug development and approval process. The FDA even said that 2020 was a strong year
Read More
The Q1 and Q2 2021 earnings seasons were perhaps the best in history relative to expectations. FactSet notes that for Q2, 86% of S&P 500 companies beat on the bottom line, and maybe more impressively, 76% of firms reported a positive revenue surprise.
Read More
PDUFA dates and content are essential for portfolio managers of healthcare stocks. A single positive or negative announcement from the US Food and Drug Administration (FDA) can send shares of a biotech firm soaring or turn a hot name quickly into a bear m
Read More
As inflation fears continue to ramp up and earnings season subsides, volatility has returned to global equity markets.
Read More
